The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast “ALN-PCSsc for the Treatment of

  The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable
  Webcast “ALN-PCSsc for the Treatment of Hypercholesterolemia”

Business Wire

PARSIPPANY, N.J. -- August 7, 2014

The Medicines Company (NASDAQ:MDCO) today announced that in collaboration with
Alnylam Pharmaceuticals (NASDAQ:ALNY) it will be hosting the “ALN-PCSsc for
the treatment of Hypercholesterolemia” RNAi Roundtable webcast on August 14,
2014. Event details are below.

RNAi Roundtable webcast: “ALN-PCSsc for the treatment of Hypercholesterolemia”
Thursday, August 14 @ 4:00 p.m. - 5:00 p.m. ET

  *Kevin Fitzgerald, Ph.D., Senior Director, Research, Alnylam
  *David Kallend, MBBS, Vice President and Global Medical Director, The
    Medicines Company
  *Moderator: Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and
    Chief Medical Officer, Alnylam Pharmaceuticals
  *Guest Speaker: Christie Ballantyne, M.D., Professor of Medicine,
    Physiology, and Molecular and Human Genetics, and Chief, Department of
    Medicine, Sections of Cardiology and Cardiovascular Research at Baylor
    College of Medicine

The event will be webcast live on the Investors section of Alnylam’s website, The event can be accessed through The Medicines Company’s
website in the Investors section at An audio
replay of the roundtable will be posted on the Alnylam website approximately
three hours after the event.

About The Medicines Company

The Medicines Company's purpose is to save lives, alleviate suffering and
contribute to the economics of healthcare by focusing on 3,000 leading
acute/intensive care hospitals worldwide. Its vision is to be a leading
provider of solutions in three areas: acute cardiovascular care, surgery and
perioperative care, and serious infectious disease care. The company operates
in the Americas, Europe and the Middle East, and Asia Pacific regions with
global centers today in Parsippany, NJ, USA and Zurich, Switzerland.


The Medicines Company
Neera Dahiya Ravindran, MD, +1-973-290-6044
Vice President, Investor Relations & Strategic Planning
Alnylam Pharmaceuticals
Cynthia Clayton, +1-617-551-8207
Vice President, Investor Relations & Corporate Communications
Press spacebar to pause and continue. Press esc to stop.